In this study, patients with serum CEA levels below 5 ng/mL before surgery were excluded because they were considered to have non-CEA-producing tumors and, therefore, CEA could not be used as an index for evaluation of tumor recurrence. Here, CEACAM5 is linked to neoplasm.